OQRO

Feed News

Explore

Insider trades Fund moves Congressional trades Federal contracts Screener

Yours

Watchlist Alerts Saved Ask Claude or ChatGPT

Create a free account Sign in

OQRO

Search/

Loading…

Director reported a non-open-market transaction in CORT | OQRO

Home
Insider trades
Corcept Therapeutics
Director reported a non-open-market transaction in CORT

Insider trades

Insider trade

Director reported a non-open-market transaction in CORT

Traded Mar 13, 2026 · Filed Mar 18, 2026

CORCorcept TherapeuticsCORT

25K
Shares

Why it stands out

Not classified as an open-market trade.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Mar 13, 2026
Reporting period: Not applicable
Filed with the SEC: Mar 18, 2026

DirectorIndirect holdingOther

Context

Classification

other

Code J — not an open-market trade

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001193125-26-111518

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Filed / recorded

Mar 18, 2026, 3:52 AM UTC

Added to OQRO

Oct 6, 2026, 7:14 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

CORCEPT THERAPEUTICS INC

Issuer CIK

1088856

Ticker

CORT

Reporting person

David L Mahoney

Relationship

Director

Security

Common Stock

Table

Non-derivative (Table I)

Transaction date

Mar 13, 2026

Transaction code

Shares / units

24,531

Price per share

$0.00

Acquired / disposed

Acquired (A)

Shares owned after

1,237,145

Ownership form

Indirect — Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust

Amendment

Footnotes from the filing

Transfer of shares without consideration to the David L. Mahoney and Winnifred C. Ellis 1998 Family Trust.

Around the same time

William GuyerChief Development Officer

Filed 6mo ago

20KShares · @ $21.65

Traded Apr 7 · filed 2 days later

Derivative exercise or conversion — not an open-market buy.

More Official record

William Guyer (Chief Development Officer) sold ~$819K of Corcept Therapeutics

Scheduled in advanceFiled 6mo ago

William GuyerChief Development Officer

Filed 6mo ago

20KDerivative units

Traded Apr 7 · filed 2 days later

Derivative exercise or conversion — not an open-market buy.

More Official record